Clinical Trial

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

Study acronym: ALTER-E005
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with ESCC. The primary endpoint is disease free survival (DFS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-02-19.
Status change: Not Yet Recruiting → Recruiting 2022-12-14
Trial Details
NCT Number NCT05252078
Lead Sponsor Jiangxi Provincial Cancer Hospital
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Diseases, Digestive System Neoplasms, Digestive System Diseases, Neoplasms by Site +3 more
Enrollment 30 participants
Start Date 2022-06-02
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2022-12-16